Rgx-121
Mucopolysaccharidosis Type 2
REGENXBIO Inc.gene_therapyPhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 58/ 100
- Competitive Position
- 95/ 100
Competitive context
21 Active assets in the Mucopolysaccharidosis Type 2 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Idursulfase Takeda | Phase 4 | A |
PABINAFUSP ALFA JCR Pharmaceuticals Co., Ltd. | Phase 3 | BBB |
Idursulfase Beta GC Biopharma Corp | Phase 3 | BBB |
Rituximab Takeda | Phase 4 | BB |
Tividenofusp Alfa Denali Therapeutics Inc. | Phase 2/3 | BB |
View all 29 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →